Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock
Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
Corcept Therapeutics Insider Sean Maduck Sells $2.05M of Stock
Sean Maduck sold 25,000 shares of Corcept Therapeutics Inc at $81.42 to $82.68 a share (average $81.85) in 3 transactions, worth $2.05M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 9,938 (-31.4%).
Roberto Wandenkolk Vieira, President, Oncology, sold 8,333 shares of Corcept Therapeutics Inc at $80.73 to $81.52 a share (average $80.89) in 2 transactions, worth $674K in total on Nov 2, 2026. Shares held after the trade: 3,946 (-29.8%).
Corcept Therapeutics reported a significant increase in net income to $126.8 million for the third quarter of 2026, compared to $19.7 million in the prior year, driven by a 64% increase in product revenue. The company maintained a strong balance sheet with over $1 billion in total assets and continued its stock repurchase program, though it recorded a net loss in the first quarter of the year.
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
Term
Q3 2026
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”
Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer
“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”
Bill Guyer, PharmD, Corcept’s Chief Development Officer
Corcept Therapeutics Director James N. Wilson Sells $1.15M of Stock
James N. Wilson, Director, sold 10,000 shares of Corcept Therapeutics Inc at $114.48 to $116.30 a share (average $114.81) in 3 transactions, worth $1.15M in total on Oct 15, 2026. Shares held after the trade: 1,054,543 (-0.0%).
Roberto Wandenkolk Vieira, President, Oncology, sold 8,333 shares of Corcept Therapeutics Inc at $114.52 to $116.58 a share (average $116.10) in 3 transactions, worth $967K in total on Oct 2, 2026. Shares held after the trade: 3,946 (-56.6%).
Corcept Therapeutics Insider Joseph Douglas Lyon Sells $1.16M of Stock
Joseph Douglas Lyon sold 10,000 shares of Corcept Therapeutics Inc at $115.40 to $116.54 a share (average $116.07) in 3 transactions, worth $1.16M in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 5,683 (-45.5%).
Corcept Therapeutics Insider Sean Maduck Sells $2.91M of Stock
Sean Maduck sold 25,000 shares of Corcept Therapeutics Inc at $115.54 to $116.55 a share (average $116.26) in 3 transactions, worth $2.91M in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 9,938 (-46.8%).
Sean Maduck, President of Corcept Endocrinology, is resigning effective October 1, 2026, and will be succeeded by Justin Gunn. Maduck will transition to a senior commercial advisor role under a consulting agreement paying $57,000 per month through September 2027.
Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of Corcept Therapeutics Inc at $100.82 a share, worth $29.8K in total on Sep 16, 2026. Shares held after the trade: 3,946 (-7.0%).
Corcept Therapeutics Insider Joseph Douglas Lyon Sells $1.13M of Stock
Joseph Douglas Lyon sold 10,000 shares of Corcept Therapeutics Inc at $113.32 to $114.12 a share (average $113.49) in 2 transactions, worth $1.13M in total on Sep 14, 2026. Shares held after the trade: 5,683 (-27.8%).
Corcept Therapeutics Director James N. Wilson Sells $1.11M of Stock
James N. Wilson, Director, sold 10,000 shares of Corcept Therapeutics Inc at $110.27 to $111.70 a share (average $110.69) in 3 transactions, worth $1.11M in total on Sep 15, 2026. Shares held after the trade: 1,064,543 (-0.3%).